Dr. Karie Runcie
Claim this profileColumbia University
Area of expertise
Prostate Cancer
Karie Runcie has run 3 trials for Prostate Cancer. Some of their research focus areas include:
Renal Cell Carcinoma
Karie Runcie has run 1 trial for Renal Cell Carcinoma.
Affiliated Hospitals
Columbia University
Columbia University Irving Medical Center
Clinical Trials Karie Runcie is currently running
Combination Immunotherapy
for Kidney Cancer
This trial is testing two new drugs, botensilimab and balstilimab, in patients with advanced kidney cancer who haven't been treated before. The new drugs aim to help the immune system better recognize and attack cancer cells. The study will compare these treatments over several months.
Recruiting
1 award
Phase 2
12 criteria
Neoadjuvant PARP Inhibition + Hormone Therapy
for Prostate Cancer
Phase 2 open-label, single-arm clinical trial evaluating the efficacy and safety of neoadjuvant olaparib + LHRH agonist administered for 6 months prior to radical prostatectomy (RP) in men with unfavorable intermediate-risk or high-risk localized prostate cancer. All patients must have confirmed germline or somatic select HRR alterations. Germline and somatic mutation testing will be performed as part of commercially available CLIA assays and will be validated on a uniform platform centrally all patients retrospectively. Eligible patients will receive treatment with olaparib + LHRH agonist. Following 6 months of therapy, patients will undergo RP with mandatory lymph node dissection. The lymph node dissection template will be at the discretion of the treating urologist. RP specimens will undergo pathology blinded independent central review. Following RP, patients will be followed for testosterone recovery and PSA progression.
Recruiting
1 award
Phase 2
More about Karie Runcie
Clinical Trial Related
5 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Karie Runcie has experience with
- Ipilimumab
- Nivolumab
- Canakinumab
- Spartalizumab
- BMS-986218
- Degarelix
Breakdown of trials Karie Runcie has run
Prostate Cancer
Renal Cell Carcinoma
Colon Cancer
DNA Repair Deficiency
Lynch Syndrome
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Karie Runcie specialize in?
Karie Runcie focuses on Prostate Cancer and Renal Cell Carcinoma. In particular, much of their work with Prostate Cancer has involved Stage I patients, or patients who are Stage II.
Is Karie Runcie currently recruiting for clinical trials?
Yes, Karie Runcie is currently recruiting for 2 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Karie Runcie has studied deeply?
Yes, Karie Runcie has studied treatments such as Ipilimumab, Nivolumab, Canakinumab.
What is the best way to schedule an appointment with Karie Runcie?
Apply for one of the trials that Karie Runcie is conducting.
What is the office address of Karie Runcie?
The office of Karie Runcie is located at: Columbia University, New York, New York 10032 United States. This is the address for their practice at the Columbia University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.